FL-ETT
9.7.2024 20:26:35 CEST | Business Wire | Press release
ETT | iByond™, together with WorldVuer established WorldVuer iByond’s joint venture to develop the world’s first artificial intelligence operating system, WiOS (WorldVuer iByond Operating System). This collaboration is poised to modernize the technology estates of global enterprises, multinationals, sovereigns, and governments, leveraging intelligent interoperability, speed of innovation, AI, and an airtight security platform. “WiOS is poised to be one of the next big players to dominate the world stage alongside Android and iOS,” concluded Mr. Michael Sutton, Chief Media Officer of WorldVuer Inc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709427149/en/
Dr. Kenneth Ekow Andam, CEO of WorldVuer Inc. & Christopher Condon, Chairman & CEO of ETT | iByond™ (Photo: Business Wire)
ETT | iByond™, renowned for its cutting-edge Intelligent Interoperability AI platform, offers seamless integration and intelligent solutions tailored to enhance business operations across various industries. With a commitment to driving technological advancement, iByond's platform empowers organizations to harness the power of AI, enabling smarter decision-making, improved efficiency, and significant cost savings for enterprises. The iByond platform will serve individual consumers with WorldVuers’ technology products. WorldVuer brings to this venture their existing ecosystem of customers, consisting of 25 countries and 98 Million households, estimated to bring this partnership USD $6 Billion+ in annual software subscription revenues. Additionally, WorldVuer has a diverse portfolio of seven pioneering technologies, each designed to push the boundaries of innovation. WorldVuer’s products are built with an emphasis on security, incorporating airtight cybersecurity measures to ensure the utmost protection for users.
“We are excited to partner with WorldVuer, a company that shares our vision of innovation and excellence,” said Christopher Condon, Chairman and CEO of ETT | iByond™. “This partnership will enable us to deliver an unparalleled AI operating system with the highest level of speed, security, and data connection helping governments and enterprises worldwide to thrive in an increasingly digital world.”
“Innovating an AI Operating System that is built to transition the current global interconnected cloud devices within our communities and countries into an efficient, corroborative, and dynamic Interoperable platform to power current and futuristic devices makes this initiative an exciting opportunity for both WorldVuer and ETT | iByond™,” commented by Dr. Kenneth Ekow Andam, CEO of WorldVuer Inc.
“As we continue to witness extensive adoption and investment in AI across the enterprise and consumer markets globally, the WorldVuer iByond operating system provides breakthrough innovation and value by integrating hardware, software, and platform technologies and services. speed, security, and scale are now in reach at a level far beyond the data management and AI solutions currently available.” Lanny Cohen, Vice-Chairman & CPO, ETT | iByond™
About WorldVuer iByond
At WorldVuer | iByond, a joint venture that provides cutting-edge intelligent technologies powered by the iByond | WiOS system, focused on Enhanced Security, Seamless Data Integration, Improved Data Governance, and Enhanced Collaboration. WorldVuer iByond provides top-tier data protection, smooth data flow, regulatory compliance, and efficient communication, empowering organizations to boost productivity, creativity, and competitiveness. For more information, visit www.worldvueribyond.com
About ETT | iByond™
ETT | iByond™ is a leading provider of transformative solutions for enterprises, specializing in software, infrastructure, and innovations. iByond empowers businesses to embrace digital transformation and unlock new avenues for growth and success in today’s rapidly evolving business environment connecting humanity through intelligent data. For more information, visit www.ettworld.com
About WorldVuer
Leaders in interactive content development. We build products to bring a lifestyle narrative and communications capabilities into your home and office. Buy WorldVuer products and join our new emerging media empowering solutions that help you build success for you and your family. For more information, visit www.wvistore.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709427149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom